Data show long-term effectiveness of GARDASIL®9 and GARDASIL® 14 years and 18 years, respectively, following vaccination with 3 doses

Data on certain HPV-related oropharyngeal cancers reinforce the importance of vaccination for both females and males

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced it will present new clinical and real-world data reaffirming the long-term effectiveness of the company's 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and its 4-valent HPV vaccine, GARDASIL® (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, from March 18-21.

Data to be presented include results from studies evaluating the long-term effectiveness of HPV vaccination in women 16 to 26 years of age, showing vaccine effectiveness for at least 14 years following 3 doses of the 9-valent vaccine, and vaccine effectiveness up to 18 years after 3 doses of the quadrivalent vaccine against HPV 16/18-related high-grade cervical disease.

The company will share additional dataoncertain HPV-related oropharyngeal cancers, and adult- and juvenile-onset Recurrent Respiratory Papillomatosis (RRP) through studies done in the U.S., Denmark, Sweden, and the United Kingdom.